{"id":54979,"date":"2023-03-20T12:05:43","date_gmt":"2023-03-20T11:05:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/"},"modified":"2023-03-20T12:05:43","modified_gmt":"2023-03-20T11:05:43","slug":"exelixis-announces-550-million-share-repurchase-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/","title":{"rendered":"Exelixis Announces $550 Million Share Repurchase Program"},"content":{"rendered":"
\n

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company\u2019s Board of Directors has authorized the repurchase of up to $550 million of the company\u2019s common stock before the end of 2023.\n<\/p>\n

<\/a><\/p>\n

\nThe timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis\u2019 common stock and general market conditions. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The program does not obligate Exelixis to acquire any particular amount of its common stock, and the share repurchase program may be modified, suspended or discontinued at any time without prior notice.\n<\/p>\n

\nAbout Exelixis<\/span><\/b>\n<\/p>\n

\nExelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX\u00ae<\/sup> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com<\/a>, follow @ExelixisInc<\/a> on Twitter, like Exelixis, Inc.<\/a> on Facebook and follow Exelixis<\/a> on LinkedIn.\n<\/p>\n

\nExelixis Forward-Looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, including, without limitation, statements related to Exelixis\u2019 intended share repurchases and repurchase timeframe; and Exelixis\u2019 scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis\u2019 current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Exelixis\u2019 ability to effect repurchases under the share repurchase program due to changes in stock price, corporate or other economic or market conditions; the nature of other investment opportunities Exelixis may have from time to time; and other factors affecting Exelixis discussed under the caption \u201cRisk Factors\u201d in Exelixis\u2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 7, 2023, and in Exelixis\u2019 future filings with the SEC. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.\n<\/p>\n

\nExelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nChris Senner<\/i>
Chief Financial Officer<\/i>
Exelixis, Inc.<\/i>
650-837-7240<\/i>
csenner@exelixis.com<\/a><\/i>\n<\/p>\n

\nSusan Hubbard<\/i>
EVP, Public Affairs & Investor Relations<\/i>
Exelixis, Inc.<\/i>
650-837-8194<\/i>
shubbard@exelixis.com<\/a><\/i>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company\u2019s Board of Directors has authorized the repurchase of up to $550 million of the company\u2019s common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54979","6":"format-standard","7":"category-industry"},"yoast_head":"\nExelixis Announces $550 Million Share Repurchase Program - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exelixis Announces $550 Million Share Repurchase Program - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company\u2019s Board of Directors has authorized the repurchase of up to $550 million of the company\u2019s common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-20T11:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230320005238\/en\/1679909\/21\/Exelixis_Logo_RGB_2023.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exelixis Announces $550 Million Share Repurchase Program\",\"datePublished\":\"2023-03-20T11:05:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/\"},\"wordCount\":556,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230320005238\\\/en\\\/1679909\\\/21\\\/Exelixis_Logo_RGB_2023.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/\",\"name\":\"Exelixis Announces $550 Million Share Repurchase Program - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230320005238\\\/en\\\/1679909\\\/21\\\/Exelixis_Logo_RGB_2023.jpg\",\"datePublished\":\"2023-03-20T11:05:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230320005238\\\/en\\\/1679909\\\/21\\\/Exelixis_Logo_RGB_2023.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230320005238\\\/en\\\/1679909\\\/21\\\/Exelixis_Logo_RGB_2023.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exelixis-announces-550-million-share-repurchase-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exelixis Announces $550 Million Share Repurchase Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exelixis Announces $550 Million Share Repurchase Program - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/","og_locale":"en_US","og_type":"article","og_title":"Exelixis Announces $550 Million Share Repurchase Program - Pharma Trend","og_description":"ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company\u2019s Board of Directors has authorized the repurchase of up to $550 million of the company\u2019s common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-20T11:05:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230320005238\/en\/1679909\/21\/Exelixis_Logo_RGB_2023.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exelixis Announces $550 Million Share Repurchase Program","datePublished":"2023-03-20T11:05:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/"},"wordCount":556,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230320005238\/en\/1679909\/21\/Exelixis_Logo_RGB_2023.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/","url":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/","name":"Exelixis Announces $550 Million Share Repurchase Program - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230320005238\/en\/1679909\/21\/Exelixis_Logo_RGB_2023.jpg","datePublished":"2023-03-20T11:05:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230320005238\/en\/1679909\/21\/Exelixis_Logo_RGB_2023.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230320005238\/en\/1679909\/21\/Exelixis_Logo_RGB_2023.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exelixis-announces-550-million-share-repurchase-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exelixis Announces $550 Million Share Repurchase Program"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54979"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54979\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}